GuidelineJournal of clinical pathology2015
Updated UK Recommendations for HER2 assessment in breast cancer.
Guideline in Journal of clinical pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05493683 (A Single Arm, Open Label, Multiple Center, Prospective Study of Disitamab Vedotin Combined With Tislelizumab in HER2 Positive Advanced Colorectal Cancer Failed at Least Two Lines of Systemic Treatment.), which is not on this map. Cited by 112 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Single Arm, Open Label, Multiple Center, Prospective Study of Disitamab Vedotin Combined With Tislelizumab in HER2 Positive Advanced Colorectal Cancer Failed at Least Two Lines of Systemic Treatment.
Who cites it
112 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Consensus Guidelines on Human Epidermal Growth Factor Receptor 2 (HER2)-Low Testing in Breast Cancer in Malaysia.Cancers · 2024Guideline
- Pathological Diagnosis, Work-Up and Reporting of Breast Cancer 1st Central-Eastern European Professional Consensus Statement on Breast Cancer.Pathology oncology research : POR · 2022Pooled it
- HER2 Positivity in Histological Subtypes of Salivary Gland Carcinoma: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2021Pooled it
- Co-expressed genes enhance precision of receptor status identification in breast cancer patients.Breast cancer research and treatment · 2018Pooled it
- SHR-A1811 (antibody-drug conjugate) in advanced HER2-mutant non-small cell lung cancer: a multicenter, open-label, phase 1/2 study.Signal transduction and targeted therapy · 2024Trial
- Methods for Estimating Long-Term Outcomes for Trastuzumab Deruxtecan in HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies.Targeted oncology · 2022Trial
- Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Trial
- Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT.Health technology assessment (Winchester, England) · 2020Trial
- An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper®.Breast cancer research : BCR · 2017Trial
- Accurate assessment of surgical HER2-low status based on core needle biopsy data of breast cancer.Diagnostic and prognostic research · 2026Article
- Detection Strategies for HER2 and miR-21 in Breast Cancer: Current Approaches and Future Perspectives- Hybrid Systematic Review and Bibliometric Mapping.Diagnostics (Basel, Switzerland) · 2026Review
- Deep-Learning Solution Providing Molecular Marker Subtyping of Breast Cancer Whole Slide Images: Protocol for a UK Clinical Service Evaluation Study.JMIR research protocols · 2026Article
- Intra-slide calibration technology improves immunohistochemical harmonization within and between anatomic pathology laboratories.bioRxiv : the preprint server for biology · 2026Article
- Population Pharmacokinetics of Trastuzumab Rezetecan in Patients With HER2-Expressing or Mutated Advanced Solid Tumors.CPT: pharmacometrics & systems pharmacology · 2026Article
- Unmet support and information needs of relatives of patients with advanced or metastatic breast cancer: results of the BRE-BY-MED study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Medication adherence in a German cohort of patients with advanced or metastatic breast cancer: results of the BRE-BY-MED study.BMC cancer · 2026Article
- Intra- and peritumoral radiomics for predicting equivocal HER2 status of breast cancer on contrast-enhanced mammography.Frontiers in oncology · 2026Article
- HER2 expression in breast cancer: evidence gaps and challenges.NPJ precision oncology · 2025Review
- Outcome prediction of oestrogen receptor-positive breast cancer based on a panel of oestrogen receptor-regulated genes.Histopathology · 2025Article
- H&E to IHC virtual staining methods in breast cancer: an overview and benchmarking.NPJ digital medicine · 2025Review
52 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human epidermal growth factor receptor 2 (HER2) overexpression is present in approximately 15% of early invasive breast cancers, and is an important predictive and prognostic marker. The substantial benefits achieved with anti-HER2 targeted therapies in patients with HER2-positive breast cancer have emphasised the need for accurate assessment of HER2 status. Current data indicate that HER2 test accuracy improved following previous publication of guidelines and the implementation of an external quality assessment scheme with a decline in false-positive and false-negative rates. This paper provides an update of the guidelines for HER2 testing in the UK. The aim is to further improve the analytical validity and clinical utility of HER2 testing by providing guidelines of test performance parameters, and recommendations on the postanalytical interpretation of test results. HER2 status should be determined in all newly diagnosed and recurrent breast cancers. Testing involves immunohistochemistry with >10% complete strong membrane staining defining a positive status. In situ hybridisation, either fluorescent or bright field chromogenic, is used either upfront or in immunohistochemistry borderline cases to detect the presence of HER2 gene amplification. Situations where repeat HER2 testing is advised are outlined and the impact of genetic heterogeneity is discussed. Strict quality control and external quality assurance of validated assays are essential. Testing laboratories should perform ongoing competency assessment and proficiency tests and ensure the reliability and accuracy of the assay. Pathologists, oncologists and surgeons involved in test interpretation and clinical use should adhere to published guidelines and maintain accurate performance and consistent interpretation of test results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.